We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Linked Antibodies Provide Universal Protection from Influenza Infection

By LabMedica International staff writers
Posted on 22 Nov 2018
A potential universal vaccine that would protect individuals from infection by all strains of influenza virus is based on multidomain antibodies that were fabricated by combining selected llama single-domain antibodies.

Vaccines remain essential for influenza prevention, but their efficacy is substantially reduced in the elderly, who are at increased risk of influenza-related complications. More...
Annual selection of vaccine strains presents many challenges, and a poor match with circulating viruses can result in limited effectiveness. Moreover, most vaccine-induced antibodies are directed against the highly variable head region of hemagglutinin (HA) and are strain specific.

In addition to the normal antibodies found in other mammals, llamas produce a unique type of antibodies, which lack the light chain. These so-called heavy-chain antibodies, which have been shown to be just as specific as regular antibodies, are being used to develop single-domain antibodies with potential pharmaceutical applications. In this regard, investigators at the Scripps Research Institute (La Jolla, CA, USA) and their collaborators extended the potential usefulness of these antibodies by combining several into a single molecule – a multidomain antibody.

For this study two llama antibodies against influenza A and two against influenza B were linked to create a multidomain antibody. The investigators reported in the November 2, 2018, issue of the journal Science that multidomain antibody MD3606 protected mice against influenza A and B infection when administered by nasal inhalation or when it was expressed from an engineered gene administered via a recombinant adeno-associated virus vector. Crystal and single-particle electron microscopy structures of these antibodies with hemagglutinins from influenza A and B viruses revealed binding to highly conserved epitopes.

The investigators concluded that they had devised an alternative strategy for long-lasting protection in which single-domain antibodies with influenza A or B reactivity were linked together into a multidomain antibody and expressed at the nasopharyngeal mucosa through the intranasal administration of a recombinant adeno-associated virus (AAV) vector encoding the multidomain antibody transgene.

Related Links:
Scripps Research Institute


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Staining Management Software
DakoLink
New
Drug Test Kit
DrugCheck 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.